Reduced mortality due to phlebotomy in moderately iron-loaded HFE haemochromatosis? The need for clinical trials  by Delatycki, Martin B. et al.
in the subgroup within the Milan criteria (Log-rank test, p <0.05).
Similar results were obtained in the subgroup beyond the Milan
criteria but within the up-to-seven criteria and the subgroup
beyond the up-to-seven criteria (Log-rank test, all p <0.05).
Taken together, although we demonstrated the clinical signif-
icance of the response to TACE at an early time point, further
studies are required for extended applications of surgical resec-
tion in patients with BCLC B stage HCC as well as those with
BCLC A stage HCC and Child-Pugh A class liver function, but a
morphologically cirrhotic liver.
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Letters to the Editor
2
OReduced mortality due to phlebotomy in moderately iron-loaded
HFE haemochromatosis? The need for clinical trialswas not seen among those with normal SF at diagnosis. Of
those who did have information about the amount of iron
removed, there is no information about whether they contin-
ued venesection therapy in order to maintain a SF level
<50 lg/L after a SF of <50 lg/L was achieved initially, or the
extent to which follow-up data (number and volume of phle-
botomies, clinical and biochemical indicators of tolerance and
efﬁcacy of venesection therapy) were available. Moreover,
there is no information about a formal, standardized, consis-
tent, cohort-wide protocol around advising participants to
start, continue and potentially stop venesection therapy,
which makes the claim that the results can be interpreted as
‘‘intention-to-treat’’ difﬁcult to justify.
Reasons other than the beneﬁt of normalization of SF that
could explain the study ﬁndings include:
1. Having a mild excess of iron in the body reduces the risk of
cardiovascular and extra-hepatic cancer. This is counter intui-
tive with data suggesting that iron is a pro-oxidant and there-
fore more likely to result in increased cancer incidence. In
addition we found an increase in the incidence of breast and
colorectal cancer in a large cohort of HFE p.C282Y homozy-
gotes compared to a matched HFE wild-type control group,
we did not, however, have sufﬁcient data to examine the
association of cancer occurrence with SF levels [3]. From theTo the Editor:
We read with interest the paper by Bardou-Jacquet and col-
leagues [1] examining mortality in HFE-associated hemochro-
matosis and the accompanying editorial [2]. Both the authors of
the study and the writers of the editorial concluded that the
observation that HFE p.C282Y homozygotes with a serum ferritin
(SF) at diagnosis between the upper limit of normal (ULN) and
1000 lg/L have reduced mortality compared to the population
at large is predominantly due to venesection therapy.
We are not convinced however, that this conclusion is sup-
ported by the data provided for the following reasons:
1. If normalization of SF resulted in reduced mortality then it
would be expected that HFE p.C282Y homozygotes with nor-
mal SF at diagnosis would also have reduced mortality but this
was not found to be the case.
2. There was no information about the amount of iron removed
for 36% of subjects so there was likely to be a signiﬁcant
minority of individuals with SF between the ULN and
1000 lg/L who did not have normalization of SF.
3. The cohort had a follow-up mean duration of 8.3 ± 3.9 years.
The average age at diagnosis was 45.2 ± 14.2 years. This means
that it is likely that many subjects in the group with SF
between the ULN and 1000 lg/L had a raised SF for many
more years than they had a normalized SF. It is not at all clear
how this balance would result in reduced mortality when this82 Journal of Hepatology 2015 vol. 63 j 276–288
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cardiovascular standpoint, there is evidence that low hepcidin
levels that are associated with HFE p.C282Y homozygosity,
leads to low reticuloendothelial cell iron levels despite
high total body iron and that this can lead to reduced
levels of atherosclerosis (the so called ‘‘hemochromatosis
paradox’’) [4].
2. As noted by the authors, those with SF between the ULN and
1000 lg/L had increased medical care compared to the
average person and this may have resulted in other lifestyle
changes that were beneﬁcial. For example lifestyle changes
in subjects with fatty liver disease such as diet and exercise,
can improve liver function and morbidity. No information is
given by the authors on body mass index and any changes
in this following appropriate intervention.
3. Individuals with SF between ULN and 1000 lg/L are less prone
to iron deﬁciency anemia and this may result in health beneﬁt.
The only way to answer the question of the role of venesection
therapy in HFE p.C282Y homozygotes with SF between ULN and
1000 lg/L is to do a randomized study with half the cohort
having normalization of SF and the other half not being treated.
Until such data are available, the question of beneﬁt from treating
HFE p.C282Y homozygotes with SF between ULN and 1000 lg/L
remains, in our view, unproven.
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Reply to: ‘‘Reduced mortality due to phlebotomy in moderately
iron-loaded HFE Haemochromatosis? The need for clinical trials’’
To the Editor:
Australian colleagues raise concerns about our study [1], and the
accompanying editorial [2]. We showed that HFE C282Y homozy-
gotes with initial serum ferritin (SF) between the upper limit of
normal and 1000 lg/L had signiﬁcantly lower overall mortality
than that of the general French population. Delatycki et al. dis-
agree with our conclusion that this could be due to early manage-
ment of patients, and putatively to the maintenance of low body
iron stores through iron removal.
With respect to their comments about methodological
aspects, we would like to stress the following points:
- We were able to provide the amount of iron removed in 64% of
our patients. This high proportion demonstrates the efﬁcacy of
our recommendations. However, we agree that, for a signiﬁ-
cant number of patients, we had no reliable information about
long-term maintenance therapy. Therefore, we have been cau-
tious when discussing the putative role of venesection therapy
in lowering mortality rate.
- Since the early 1990s, we deliver written guidelines and a per-
sonal follow-up notebook to every C282Y homozygote. With
time, our recommendations did not vary with respect to the
indications and management of initial and maintenance of
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